Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

SeaSpine Holdings Corporation (SPNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.35-0.11 (-1.47%)
At close: 04:00PM EDT
7.34 -0.01 (-0.20%)
After hours: 04:05PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • E
    ELIZABETH
    Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $21.00 price target on SeaSpine Holdings (NASDAQ: SPNE), following the company's Q1 report.

    The analyst comments: "We reiterate our Overweight rating and 12-month price target of $21 on SeaSpine Holdings (SPNE) following the company reporting above-consensus 1Q22 revenue and raising its CY22 guidance. Specifically, SPNE reported 1Q22 revenue of $50.7 million (Cantor $49.2 million / FactSet Consensus $49.0 million), implying year-over-year growth of 21% driven by U.S. Spinal Implant and Enabling Technologies growth of 31%. Importantly, SPNE noted an improving operating environment starting in February with hospital staffing and operating-room capacity headwinds subsiding, resulting in strong spine procedure volumes. The company noted that this positive trend continued through April and expects the operating environment to continue to improve for the balance of the year. As a result, SPNE increased its CY22 revenue guidance from the prior range of $226 to $230 million to the revised range of $231 to $235 million (Pre-Call FactSet Consensus: $228 million). Based on SPNE's strong 1Q despite a weak January, the company's positive outlook for the balance of the year and a core business that is set to be bolstered by new, faster-growing and higher-margin products, we continue to believe that CY22 will prove to be a productive year for SPNE, and that this will likely be reflected in potential share price appreciation. Accordingly, we reiterate our Overweight rating and encourage investors to acquire SPNE's shares at what we believe is currently an attractive valuation."
  • g
    georgian
    Trading without this tool is like going in blind. I adore this tool, it is a game changer. Loving it so far. Absolutely hands down the best trading software you should invest in well worth every penny! I am sure you will love it! https://daytrading.tools/Trade-of-the-Week
  • B
    Buddha Bro
    Hello anyone else following this stock??
  • D
    DEAN
    If it was normal times I would say the results are disappointing. But under the circumstances I see increased revenues regardless. No long term debt. Good cash reserves. And a seemingly responsible management with a product with world wide potential.
    Some comments would really be appreciated. Thanks.
  • l
    lewis
    to the moon
  • Y
    Yahoo Finance Insights
    SPNE is down -4.92% to 10.82
  • M
    Michael
    What's driving the downward push today? Can't find any news or press releases!
  • Y
    Yahoo Finance Insights
    SPNE is up 9.60% to 11.20
  • Y
    Yahoo Finance Insights
    SPNE is up 5.12% to 10.63
  • Y
    Yahoo Finance Insights
    SPNE is up 5.17% to 11.18
  • Y
    Yahoo Finance Insights
    SPNE is up 6.05% to 10.34
  • Y
    Yahoo Finance Insights
    SPNE is up 9.73% to 13.76
  • Y
    Yahoo Finance Insights
    SPNE is up 7.10% to 13.12
  • Y
    Yahoo Finance Insights
    SPNE is up 5.94% to 14.09
  • Y
    Yahoo Finance Insights
    SPNE is up 7.69% to 11.06
  • Y
    Yahoo Finance Insights
    SPNE is up 5.82% to 11.63
  • Y
    Yahoo Finance Insights
    SPNE is up 5.35% to 10.43
  • Y
    Yahoo Finance Insights
    SPNE is down -56.89% to 11.86
  • Y
    Yahoo Finance Insights
    SPNE is down -5.20% to 10.03
Advertisement
Advertisement